Solid Biosciences Inc. (SLDB)
Solid Biosciences Statistics
Share Statistics
Solid Biosciences has 77.49M shares outstanding. The number of shares has increased by 101.91% in one year.
| Shares Outstanding | 77.49M |
| Shares Change (YoY) | 101.91% |
| Shares Change (QoQ) | 93.95% |
| Owned by Institutions (%) | 89.01% |
| Shares Floating | 64.4M |
| Failed to Deliver (FTD) Shares | 6.72K |
| FTD / Avg. Volume | 0.26% |
Short Selling Information
The latest short interest is 8.62M, so 11.12% of the outstanding shares have been sold short.
| Short Interest | 8.62M |
| Short % of Shares Out | 11.12% |
| Short % of Float | 13.24% |
| Short Ratio (days to cover) | 7.93 |
Valuation Ratios
The PE ratio is -1.31 and the forward PE ratio is -1.73. Solid Biosciences's PEG ratio is 0.04.
| PE Ratio | -1.31 |
| Forward PE | -1.73 |
| PS Ratio | 0 |
| Forward PS | 0.7 |
| PB Ratio | 1.19 |
| P/FCF Ratio | -1.62 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Solid Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.2, with a Debt / Equity ratio of 0.18.
| Current Ratio | 5.2 |
| Quick Ratio | 5.2 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | -0.19 |
| Debt / FCF | -0.24 |
| Interest Coverage | 381.55 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.25M |
| Employee Count | 100 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -63.36% in the last 52 weeks. The beta is 2.07, so Solid Biosciences's price volatility has been higher than the market average.
| Beta | 2.07 |
| 52-Week Price Change | -63.36% |
| 50-Day Moving Average | 4.35 |
| 200-Day Moving Average | 5.72 |
| Relative Strength Index (RSI) | 46.33 |
| Average Volume (20 Days) | 2.61M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -129.73M |
| Net Income | -124.7M |
| EBITDA | -129.73M |
| EBIT | -125.04M |
| Earnings Per Share (EPS) | -3.06 |
Balance Sheet
The company has 80.23M in cash and 24.18M in debt, giving a net cash position of 56.06M.
| Cash & Cash Equivalents | 80.23M |
| Total Debt | 24.18M |
| Net Cash | 56.06M |
| Retained Earnings | -783.45M |
| Total Assets | 188.66M |
| Working Capital | 127.05M |
Cash Flow
In the last 12 months, operating cash flow was -100.01M and capital expenditures -654K, giving a free cash flow of -100.67M.
| Operating Cash Flow | -100.01M |
| Capital Expenditures | -654K |
| Free Cash Flow | -100.67M |
| FCF Per Share | -2.47 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLDB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SLDB is $15.5, which is 371.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.5 |
| Price Target Difference | 371.1% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Stock Splits
The last stock split was on Oct 28, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Oct 28, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -3.99 |
| Piotroski F-Score | 2 |